Michael Patrick Miller - 11 Nov 2026 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

SEC form
4
Accepted by SEC
13 Nov 2026, 19:36:26 UTC
Prior SEC filing
15 Jun 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Michael Patrick Miller filed Form 4 for PUMA BIOTECHNOLOGY, INC. (PBYI) on 13 Nov 2026.

Key facts

  • This page summarizes Michael Patrick Miller's Form 4 filing for PUMA BIOTECHNOLOGY, INC. (PBYI).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 13 Nov 2026, 19:36.

Change

  • Previous filing in this sequence was filed on 15 Jun 2026.
  • Current net transaction value: -$121,456.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001236514 Primary reporting owner

MILLER MICHAEL PATRICK

Relationship
Director

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PBYI transaction

Common Stock

Sale

Transaction value
-$121,456
Shares
-15,000
Change %
-19%
Price
$8.10
Shares after
66,000
Date
11 Nov 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.04 to $8.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .